Literature DB >> 10666480

Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.

A K Topaloglu1, G A Ashley, B Tong, J Shabbeer, K H Astrin, C M Eng, R J Desnick.   

Abstract

BACKGROUND: Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from the deficient activity of the lysosomal exoglycohydrolase alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A). The nature of the molecular lesions in the alpha-Gal A gene in 30 unrelated families was determined to provide precise heterozygote detection, prenatal diagnosis, and define genotype-phenotype correlations.
MATERIALS AND METHODS: Genomic DNA was isolated from affected males and/or carrier females from 30 unrelated families with Fabry disease. The entire alpha-Gal A coding region and flanking intronic sequences were analyzed by PCR amplification and automated sequencing.
RESULTS: Twenty new mutations were identified, each in a single family: C142R, G183D, S235C, W236L, D244H, P259L, M267I, I289F, Q321E, C378Y, C52X, W277X, IVS4(+4), IVS6(+2), IVS6(-1), 35del13, 256del1, 892ins1, 1176del4, and 1188del1. In the remaining 10 unrelated Fabry families, 9 previously reported mutations were detected: M42V, R112C, S148R, D165V, N215S (in 2 families), Q99X, C142X, R227X, and 1072del3. Haplotype analysis using markers closely flanking the alpha-Gal A gene indicated that the two patients with the N215S lesion were unrelated. The IVS4(+4) mutation was a rare intronic splice site mutation that causes Fabry disease.
CONCLUSIONS: These studies further define the heterogeneity of mutations in the alpha-Gal A gene causing Fabry disease, permit precise heterozygote detection and prenatal diagnosis, and help delineate phenotype-genotype correlations in this disease. </AB

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10666480      PMCID: PMC2230489     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  12 in total

1.  Amplification of human polymorphic sites in the X-chromosomal region q21.33 to q24: DXS17, DXS87, DXS287, and alpha-galactosidase A.

Authors:  R Kornreich; K H Astrin; R J Desnick
Journal:  Genomics       Date:  1992-05       Impact factor: 5.736

2.  Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene.

Authors:  C M Eng; D J Niehaus; A L Enriquez; T S Burgert; M D Ludman; R J Desnick
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

3.  Nucleotide sequence of the human alpha-galactosidase A gene.

Authors:  R Kornreich; R J Desnick; D F Bishop
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

4.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

5.  Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes.

Authors:  R J Desnick; K Y Allen; S J Desnick; M K Raman; R W Bernlohr; W Krivit
Journal:  J Lab Clin Med       Date:  1973-02

Review 6.  Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.

Authors:  C M Eng; R J Desnick
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

7.  Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease.

Authors:  H Sakuraba; A Oshima; Y Fukuhara; M Shimmoto; Y Nagao; D F Bishop; R J Desnick; Y Suzuki
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

8.  Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme.

Authors:  D F Bishop; D H Calhoun; H S Bernstein; P Hantzopoulos; M Quinn; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

9.  Fabry disease: molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1.

Authors:  M Caggana; G A Ashley; R J Desnick; C M Eng
Journal:  Am J Med Genet       Date:  1997-08-22

10.  Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.

Authors:  C M Eng; L A Resnick-Silverman; D J Niehaus; K H Astrin; R J Desnick
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

View more
  26 in total

1.  Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Robin L Bennett; Kimberly A Hart; Erin O'Rourke; John A Barranger; Jack Johnson; Kay D MacDermot; Gregory M Pastores; Robert D Steiner; Ravi Thadhani
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

2.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

3.  Mutational analysis of the GLA gene in Mexican families with Fabry disease.

Authors:  Bianca Ethel Gutiérrez-Amavizca; Andreas Gal; Rocío Ortíz-Orozco; Ulrich Orth; Ernesto Prado Montes De Oca; Jaime Paul Gutiérrez-Amavizca; Luis E Figuera
Journal:  J Genet       Date:  2017-03       Impact factor: 1.166

4.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

5.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.

Authors:  Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira
Journal:  Mol Genet Metab       Date:  2014-11-09       Impact factor: 4.797

6.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

7.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

Review 8.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

9.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

10.  Persistent increase in cardiac troponin I in Fabry disease: a case report.

Authors:  Christian Tanislav; Andreas Feustel; Wolfgang Franzen; Oliver Wüsten; Christian Schneider; Frank Reichenberger; Arndt Rolfs; Nicole Sieweke
Journal:  BMC Cardiovasc Disord       Date:  2011-01-31       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.